Search alternatives:
teer decrease » greater decrease (Expand Search)
ht decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
teer decrease » greater decrease (Expand Search)
ht decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1161
Table_1_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1162
Table_6_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1163
Table_11_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1164
Image_4_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1165
Table_9_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1166
Table_14_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1167
Table_15_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1168
Table_2_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1169
Image_2_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1170
Table_4_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1171
Table_10_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1172
Image_1_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.TIF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1173
Table_3_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1174
Table_7_Tramadol’s Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.PDF
Published 2018“…To investigate whether other mechanisms contribute to the inhibitory effects, WAY100,635, a 5-HT<sub>1A</sub> receptor antagonist and naloxone, a μ-opioid receptor antagonist, were tested on sexual behavior together with tramadol. …”
-
1175
List of Included studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1176
The search strategy in three databases.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1177
NIH score.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1178
List of excluded studies.
Published 2025“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”
-
1179
-
1180
Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner.
Published 2013“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”